Free tool
FAERS Monitor: Metopirone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012911 or its brand name (Metopirone, Metyrapone). Reports on generic versions are filed under their own applications.
Reports
999
Serious
675
68% of reports
Hospitalization
323
Death reported
125
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use383
- nausea81
- drug ineffective66
- fatigue53
- vomiting53
- adrenal insufficiency45
- asthenia41
- dizziness41
- death38
- maternal exposure during pregnancy35
- pneumocystis jirovecii pneumonia35
- diarrhoea33
- anaemia28
- hypokalaemia27
- premature baby27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 3 |
| 2006 | 9 |
| 2007 | 11 |
| 2008 | 3 |
| 2009 | 10 |
| 2010 | 13 |
| 2011 | 16 |
| 2012 | 26 |
| 2013 | 29 |
| 2014 | 11 |
| 2015 | 15 |
| 2016 | 17 |
| 2017 | 34 |
| 2018 | 82 |
| 2019 | 31 |
| 2020 | 57 |
| 2021 | 79 |
| 2022 | 83 |
| 2023 | 80 |
| 2024 | 138 |
| 2025 | 132 |
| 2026 | 114 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,160 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| adrenal insufficiencySignal | 45 | 78.4 | 58.9 | 3,349 |
| pneumocystis jirovecii pneumoniaSignal | 35 | 73.6 | 53.2 | 2,429 |
| premature babySignal | 27 | 18.9 | 13.0 | 440 |
| hypokalaemiaSignal | 27 | 12.3 | 8.5 | 270 |
| off label useSignal | 383 | 9.2 | 8.5 | 2,916 |
| maternal exposure during pregnancySignal | 35 | 8.3 | 6.0 | 217 |
| anaemiaSignal | 28 | 3.1 | 2.1 | 38 |
| vomitingSignal | 53 | 2.4 | 1.8 | 42 |
| astheniaSignal | 41 | 2.3 | 1.7 | 29 |
| nauseaSignal | 81 | 2.2 | 1.7 | 51 |
| dizziness | 41 | 1.7 | 1.3 | 12 |
| fatigue | 53 | 1.4 | 1.1 | 7 |
| diarrhoea | 33 | 1.1 | 0.8 | 0 |
| drug ineffective | 66 | 1.1 | 0.8 | 0 |
| death | 38 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.